RT Journal Article
SR Electronic
T1 Low dose hydroxychloroquine prophylaxis for COVID-19 – a prospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21262971
DO 10.1101/2021.09.13.21262971
A1 RE-HCP2 COVID study group
A1 Mayank Agarwal
A1 Rajat Ranka
A1 Prasan Kumar Panda
A1 Ajay Kumar
A1 Gaurav Chikara
A1 Suresh K Sharma
A1 Rizu Negi
A1 Ramanuj Samanta
A1 Rohit Walia
A1 Yogesh Arvind Bahurupi
A1 Sarama Saha
A1 Minakshi Dhar
A1 Prakhar Sharma
A1 Arvind Kumar Gupta
A1 UB Mishra
A1 Manoj Kumar Gupta
A1 Ravi Kant
YR 2021
UL http://medrxiv.org/content/early/2021/09/14/2021.09.13.21262971.abstract
AB Background Since the outbreak of COVID-19 pandemic, the world began a frantic search for possible prophylactic options. While trials on hydroxychloroquine (HCQ) prophylaxis are ongoing, concrete evidence is lacking. The study aimed to determine the relative efficacy of various doses of oral HCQ in prophylaxis and mitigating the severity of COVID-19 in healthcare workers.Methods This was a prospective cohort with four arms (high, medium, low dose, and control) of HCQ prophylaxis, used by healthcare workers at a tertiary care center in India. Participants were grouped as per their opting for any one arm on a voluntary basis as per institute policy under the Government guidance. The outcomes studied were COVID-19 positivity by RT-PCR and its severity assessed by WHO COVID-19 severity scale.Results Total 486 participants were enrolled, of which 29 (6%) opted for low dose, 2 (<1%) medium dose, and none for high dose HCQ while 455 (93.6%) were in the control arm. Of the 164 participants who underwent RT-PCR, 96 (58.2%) tested positive. Out of these 96 positive cases, the majority of them (79 of 96 [82.3%]) were ambulatory and were managed conservatively at home. Only 17.7% (17 of 96) participants, all of them from the control group, required hospitalization with the mild-moderate disease. None of the participants had severe disease, COVID-related complications, ICU stay, or death. The difference in the outcome assessed amongst the various arms was statistically insignificant (p value >0.05).Conclusion This single-center study demonstrated that HCQ prophylaxis in healthcare workers does not cause a significant reduction in COVID-19 as well as mitigating its severity in those infected. At present, most of the trials have not shown any benefit. The debate continues to rage, should HCQ prophylaxis be given to healthcare workers for chemoprophylaxis?Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/06/025593Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was done after institute ethical approval (Institutional Ethics Committee at All India Institute of Medical Sciences, Rishikesh) and as per declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter obtaining approval from corresponding author, de-identified data can be shared.